Eliquis(Apixaban)
BMY
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Bristol-Myers Squibb Company
$20.77B
Medicare cost, 2024
$20.77B
Medicare cost, 2024
Medicare drug plans spent $20.8 billion on Eliquis (apixaban) in 2024, for 24.1 million prescriptions and refills filled by 4.4 million patients. It is the drug Medicare drug plans spend the most on. Florida accounts for the most spending ($1.6 billion, 8% of the total). It is made by Bristol-Myers Squibb Company (BMY).
Medicare cost, 2024
$20.77B
+13.7% from 2023
Prescriptions
24.1M
$863.42 per claim
Patients
4.4M
556,431 prescribers
Total spending, 2024
$20.77B
$4,695.12 per patient
Questions and answers
How much does Medicare spend on Eliquis?
Medicare prescription drug plans paid $20.77B for Eliquis in 2024, for 24,054,695 prescriptions and refills to 4,423,497 patients (up 13.7% from 2023). The average cost per claim was $863.42.
Which state spends the most on Eliquis?
Florida had the highest Medicare cost for Eliquis in 2024: $1.58B for 1,734,859 claims, followed by California ($1.58B).
Who prescribes Eliquis the most?
Jennifer L Tresser, pharmacist in Martinez, CA, had the highest Medicare cost for Eliquis in 2024: 5,156 claims costing $8.7M.
Who makes Eliquis?
Eliquis is made by Bristol-Myers Squibb Company (BMY), listed in the Medicare spending data as BMS Primarycare.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Eliquis was $20.77B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Eliquis, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Jennifer L Tresser Martinez, CA | Pharmacist | 5,156 | 1,953 | $8.7M |
| Huong K Ha Sepulveda, CA | Pharmacist | 2,983 | 1,087 | $4.5M |
| Elena M Wellen Wilmington, NC | Pharmacist | 2,698 | 1,075 | $4.4M |
| Cindy S Kennedy Charlotte, NC | Pharmacist | 2,569 | 851 | $4.0M |
| Carmen Wong Union City, CA | Pharmacist | 2,620 | 950 | $3.9M |
| Wassim Shaheen Wichita, KS | Interventional Cardiology | 3,943 | 765 | $3.7M |
| Jeanne C Benoit Quincy, MA | Nurse Practitioner | 3,125 | 828 | $3.7M |
| Hyeon Hye Lee Cupertino, CA | Pharmacist | 2,298 | 882 | $3.7M |
| Samantha J Seivert Wilmington, NC | Pharmacist | 2,217 | 1,005 | $3.5M |
| Mohamed H Khan Redding, CA | Interventional Cardiology | 2,431 | 716 | $3.5M |
| Robert J Pearlstein Plymouth Meeting, PA | Internal Medicine | 13,468 | 1,101 | $3.5M |
| Jordan Wong San Francisco, CA | Pharmacist | 2,178 | 774 | $3.3M |
| Glenn H Herrington Wilmington, NC | Pharmacist | 1,900 | 914 | $3.1M |
| Maria R Peluso Winston Salem, NC | Pharmacist | 1,914 | 671 | $3.1M |
| Gad A Silberman Tallahassee, FL | Clinical Cardiac Electrophysiology | 3,713 | 564 | $2.7M |
| Michael P Boyle Ocean View, DE | Nurse Practitioner | 2,054 | 754 | $2.7M |
| Mischell E Schlosser Toledo, OH | Nurse Practitioner | 2,387 | 920 | $2.6M |
| Timir S Baman Peoria, IL | Clinical Cardiac Electrophysiology | 2,010 | 517 | $2.5M |
| Mayer Rashtian Pasadena, CA | Clinical Cardiac Electrophysiology | 2,105 | 544 | $2.4M |
| Zoheir A Abdelbaki Lima, OH | Cardiology | 1,962 | 532 | $2.4M |
| Hazar Dahhan Manchester, CT | Cardiology | 1,730 | 424 | $2.4M |
| Lance E Sullenberger Albany, NY | Cardiology | 1,578 | 482 | $2.3M |
| Jeannie Poon Mooresville, NC | Pharmacist | 1,473 | 490 | $2.3M |
| Majed Nounou Lapeer, MI | Interventional Cardiology | 1,857 | 525 | $2.3M |
| Samantha J Bialecki Toledo, OH | Nurse Practitioner | 2,033 | 806 | $2.3M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 496,989 | 18,969,114 | 3,504,386 | $15.22B |
| 2023 | 526,725 | 21,185,751 | 3,925,487 | $18.27B |
| 2024 | 556,431 | 24,054,695 | 4,423,497 | $20.77B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| BMS Primarycare | 24,061,332 | $20.77B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 28
- RxNorm concept IDs
- 1364435, 1364441, 1364445, 1364447
- Application numbers
- NDA202155
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 68,069 side-effect reports named apixaban, the active ingredient of Eliquis (reports from 2005 on). 65,146 of them (95.7%) were serious, 7,416 named a death and 30,037 named a hospital stay. The reactions named most often were atrial fibrillation, dyspnoea and cerebrovascular accident. 27,297 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
68,069
5,896 in 2025 (+3.2% from 2024)
Serious
95.7%
65,146 reports
Deaths named
7,416
10.9% of reports
Hospital stays
30,037
44.1% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Eliquis?
68,069 reports from 2005 through September 2026 named apixaban, the active ingredient of Eliquis. 65,146 of them (95.7%) were serious, 7,416 named a death and 30,037 named a hospital stay.
What are the most reported side effects of Eliquis?
4,134 reports named atrial fibrillation, the reaction named most often, followed by dyspnoea (3,850) and cerebrovascular accident (3,610). In the last 5 years the reaction named most often was off label use (1,966 reports). A report can name several reactions.
How many side-effect reports named Eliquis in 2025?
5,896 reports were received in 2025 (+3.2% from 2024). 2026 so far: 5,296 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Eliquis caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Eliquis caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
BMY·BMY drug pipeline - Drug approvals (1 approval on file for apixaban) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (apixaban) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.